Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A non-Hodgkin lymphoma that arises from the central nervous system.
Biomarker and diagnostic research for central nervous system non-hodgkin lymphoma has been reported in the published literature.
2 clinical trials registered. Interventions under study include drug therapy, medical devices, and procedural interventions. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
140 publications have been identified in PubMed for central nervous system non-hodgkin lymphoma. Research spans Review / Meta-Analysis (23%), Clinical Trial Publication (20%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 32 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 8:51 PM UTC
Clinical study results | 28 | 20% |
Disease patterns and progression | 22 | 16% |
Patient case studies | 20 | 14% |
Laboratory research | 16 | 11% |
Testing and diagnosis research | 15 | 11% |
New treatment approaches | 7 | 5% |
Li C (2026). [PMID: 41352379](https://pubmed.ncbi.nlm.nih.gov/41352379/). *Free Radic Biol Med*. [Basic Science / Preclinical]
Green K (2026). [PMID: 31424729](https://pubmed.ncbi.nlm.nih.gov/31424729/). *Unknown Journal*. [Epidemiology / Natural History]
Fiore P (2026). [PMID: 42142971](https://pubmed.ncbi.nlm.nih.gov/42142971/). *Clin Lymphoma Myeloma Leuk*. [Review / Meta-Analysis]
Cao S (2026). [PMID: 42104165](https://pubmed.ncbi.nlm.nih.gov/42104165/). *Neurol Sci*. [Case Report / Case Series]
Falade AS (2026). [PMID: 41961024](https://pubmed.ncbi.nlm.nih.gov/41961024/). *Mayo Clin Proc*. [Review / Meta-Analysis]
Ensari N (2026). [PMID: 41276657](https://pubmed.ncbi.nlm.nih.gov/41276657/). *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery*. [Clinical Trial Publication]
Haydu JE (2026). [PMID: 41170917](https://pubmed.ncbi.nlm.nih.gov/41170917/). *Blood advances*. [Review / Meta-Analysis]
Finsterer J (2026). [PMID: 41804404](https://pubmed.ncbi.nlm.nih.gov/41804404/). *Cureus*. [Case Report / Case Series]
Alderuccio JP (2026). [PMID: 41490516](https://pubmed.ncbi.nlm.nih.gov/41490516/). *Blood*. [Clinical Trial Publication]
Fangazio M (2025). [PMID: 40658005](https://pubmed.ncbi.nlm.nih.gov/40658005/). *Current opinion in oncology*. [Review / Meta-Analysis]
AI-curated news mentioning central nervous system non-hodgkin lymphoma
Updated Sep 16, 2026
A systematic review and meta-analysis evaluates the efficacy and safety of chimeric antigen receptor T-cell therapy in treating primary central nervous system lymphoma. The findings contribute to understanding potential therapeutic options for this rare malignancy.
Recent research highlights the evolving role of radiotherapy in treating primary central nervous system lymphoma, emphasizing its integration into combined treatment strategies. This study provides insights into optimizing therapeutic approaches for improved patient outcomes.
A study reveals significant racial and socioeconomic disparities affecting survival outcomes in patients with primary central nervous system lymphoma (PCNSL) in the US. The analysis highlights systemic barriers to care and treatment heterogeneity, emphasizing the need for urgent action to address these disparities.
A systematic literature review highlights movement disorders associated with primary central nervous system lymphoma, providing insights into clinical presentations and management strategies. This case study contributes to the understanding of neurological complications linked to this rare malignancy.